BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20539088)

  • 1. Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57.
    Tang Y; Huang S; Dunkley-Thompson J; Steel-Duncan JC; Ryland EG; St John MA; Hazra R; Christie CD; Feeney ME
    AIDS; 2010 Jun; 24(10):1425-35. PubMed ID: 20539088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.
    Migueles SA; Laborico AC; Imamichi H; Shupert WL; Royce C; McLaughlin M; Ehler L; Metcalf J; Liu S; Hallahan CW; Connors M
    J Virol; 2003 Jun; 77(12):6889-98. PubMed ID: 12768008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.
    Navis M; Schellens I; van Baarle D; Borghans J; van Swieten P; Miedema F; Kootstra N; Schuitemaker H
    J Immunol; 2007 Sep; 179(5):3133-43. PubMed ID: 17709528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
    Altfeld M; Addo MM; Rosenberg ES; Hecht FM; Lee PK; Vogel M; Yu XG; Draenert R; Johnston MN; Strick D; Allen TM; Feeney ME; Kahn JO; Sekaly RP; Levy JA; Rockstroh JK; Goulder PJ; Walker BD
    AIDS; 2003 Dec; 17(18):2581-91. PubMed ID: 14685052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.
    Navis M; Schellens IM; van Swieten P; Borghans JA; Miedema F; Kootstra NA; van Baarle D; Schuitemaker H
    J Infect Dis; 2008 Mar; 197(6):871-9. PubMed ID: 18279072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.
    Jansen CA; Kostense S; Vandenberghe K; Nanlohy NM; De Cuyper IM; Piriou E; Manting EH; Miedema F; van Baarle D
    Eur J Immunol; 2005 Jan; 35(1):150-8. PubMed ID: 15593302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.
    Miura T; Brockman MA; Schneidewind A; Lobritz M; Pereyra F; Rathod A; Block BL; Brumme ZL; Brumme CJ; Baker B; Rothchild AC; Li B; Trocha A; Cutrell E; Frahm N; Brander C; Toth I; Arts EJ; Allen TM; Walker BD
    J Virol; 2009 Mar; 83(6):2743-55. PubMed ID: 19116253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.
    Chen H; Ndhlovu ZM; Liu D; Porter LC; Fang JW; Darko S; Brockman MA; Miura T; Brumme ZL; Schneidewind A; Piechocka-Trocha A; Cesa KT; Sela J; Cung TD; Toth I; Pereyra F; Yu XG; Douek DC; Kaufmann DE; Allen TM; Walker BD
    Nat Immunol; 2012 Jun; 13(7):691-700. PubMed ID: 22683743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
    Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
    J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.
    Bailey JR; Williams TM; Siliciano RF; Blankson JN
    J Exp Med; 2006 May; 203(5):1357-69. PubMed ID: 16682496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.
    Klein MR; van der Burg SH; Hovenkamp E; Holwerda AM; Drijfhout JW; Melief CJ; Miedema F
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2191-201. PubMed ID: 9747728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.
    Keane NM; Roberts SG; Almeida CA; Krishnan T; Chopra A; Demaine E; Laird R; Tschochner M; Carlson JM; Mallal S; Heckerman D; James I; John M
    Immunol Cell Biol; 2012 Feb; 90(2):224-34. PubMed ID: 21577229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal transmission of human immunodeficiency virus escape mutations subverts HLA-B57 immunodominance but facilitates viral control in the haploidentical infant.
    Schneidewind A; Tang Y; Brockman MA; Ryland EG; Dunkley-Thompson J; Steel-Duncan JC; St John MA; Conrad JA; Kalams SA; Noel F; Allen TM; Christie CD; Feeney ME
    J Virol; 2009 Sep; 83(17):8616-27. PubMed ID: 19515764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A.
    Brockman MA; Schneidewind A; Lahaie M; Schmidt A; Miura T; Desouza I; Ryvkin F; Derdeyn CA; Allen S; Hunter E; Mulenga J; Goepfert PA; Walker BD; Allen TM
    J Virol; 2007 Nov; 81(22):12608-18. PubMed ID: 17728232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.
    Matthews PC; Adland E; Listgarten J; Leslie A; Mkhwanazi N; Carlson JM; Harndahl M; Stryhn A; Payne RP; Ogwu A; Huang KH; Frater J; Paioni P; Kloverpris H; Jooste P; Goedhals D; van Vuuren C; Steyn D; Riddell L; Chen F; Luzzi G; Balachandran T; Ndung'u T; Buus S; Carrington M; Shapiro R; Heckerman D; Goulder PJ
    J Immunol; 2011 May; 186(10):5675-86. PubMed ID: 21498667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 capsids from B27/B57+ elite controllers escape Mx2 but are targeted by TRIM5α, leading to the induction of an antiviral state.
    Merindol N; El-Far M; Sylla M; Masroori N; Dufour C; Li JX; Cherry P; Plourde MB; Tremblay C; Berthoux L
    PLoS Pathog; 2018 Nov; 14(11):e1007398. PubMed ID: 30419009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired replication capacity of acute/early viruses in persons who become HIV controllers.
    Miura T; Brumme ZL; Brockman MA; Rosato P; Sela J; Brumme CJ; Pereyra F; Kaufmann DE; Trocha A; Block BL; Daar ES; Connick E; Jessen H; Kelleher AD; Rosenberg E; Markowitz M; Schafer K; Vaida F; Iwamoto A; Little S; Walker BD
    J Virol; 2010 Aug; 84(15):7581-91. PubMed ID: 20504921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
    Payne RP; Kløverpris H; Sacha JB; Brumme Z; Brumme C; Buus S; Sims S; Hickling S; Riddell L; Chen F; Luzzi G; Edwards A; Phillips R; Prado JG; Goulder PJ
    J Virol; 2010 Oct; 84(20):10543-57. PubMed ID: 20686036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.